Navigation Links
Highland Capital Partners Expands Healthcare Team
Date:10/21/2008

Bijan Salehizadeh Promoted to General Partner; Elazer Edelman Joins Firm

LEXINGTON, Mass. and MENLO PARK, Calif., Oct. 21 /PRNewswire/ -- Highland Capital Partners, a venture capital firm celebrating its 20th year of helping great people build great companies, today announced the expansion of its healthcare team. In recognition of his significant contributions to Highland and its portfolio companies, Dr. Bijan Salehizadeh has been promoted to the role of General Partner. In addition, joining the firm is Dr. Elazer Edelman, one of the foremost experts in vascular biology.

Based in the firm's Menlo Park office, Dr. Salehizadeh joined Highland in 2004 as a Senior Associate. He has specialized in early stage medical devices and biotechnology healthcare companies, and currently represents Highland on the boards of Hyperion Therapeutics and OpGen. In addition, he is or has been actively involved in Highland's investments in BAROnova, Conor Medsystems, Magen BioSciences and Predictive Biosciences.

Dr. Edelman will serve as an Advisor with the firm and focus his investment efforts on the medical technology sector. In this capacity, he'll apply his academic insight and industry vision to work with the Highland team in identifying new opportunities at the cutting edge of science and medicine. Dr. Edelman has a long history of working with the firm, including serving on the Advisory Board of Conor Medsystems (IPO; acquired by Johnson & Johnson). He is also the co-founder of Pervasis Therapeutics, a Highland-backed company pioneering regenerative cell-based therapies and devices.

"We are very excited to announce Bijan's promotion as we expand our commitment to working with best-in-class entrepreneurs and management teams," said Bob Higgins, General Partner with Highland. "Elazer is a world-class physician/researcher, and we are thrilled to have him helping us build next generation medical technology companies."

More About Dr. Bijan Salehizadeh, M.D.

Prior to joining Highland, Dr. Salehizadeh spent several years in marketing and strategic planning at Medtronic Vascular, a world leader in medical technology. Before Medtronic, he was the Director of Business Development for HealthCentral, a venture-backed start-up that went public in 1999. During his medical training, Dr. Salehizadeh conducted research in minimally invasive heart valves and left ventricular assist devices, and his work was published in several peer-reviewed scientific journals. He also served as a researcher at the National Heart, Lung, and Blood Institute where he investigated coronary artery disease.

Dr. Salehizadeh holds an A.B. in Molecular Biology from Princeton University, a M.S. in Health Policy from Columbia University, a M.D. in Medicine from Columbia University and an M.B.A. from Harvard Business School. He has also previously served as a member of the Kauffman Fellows program.

More About Dr. Elazer Edelman, M.D.

In addition to his role at Highland, Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a Coronary Care Unit cardiologist at the Brigham and Women's Hospital. In addition to directing the Harvard-MIT Biomedical Engineering Center, he runs the Edelman Laboratory, an integrated physiology research laboratory that has pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman's research melds his clinical and medical training and interests, focusing on understanding how tissue architecture and biochemical regulation contribute to local growth control.

Dr. Edelman earned a B.S. in Bioelectrical Engineering and Applied Biology from MIT, a M.S. in Electrical Engineering and Computer Sciences from MIT, a M.D. in Medicine at Harvard Medical School, and a Ph.D. in Medical Engineering and Medical Physics from MIT.

About Highland Capital Partners

Highland Capital Partners was founded with the mission of helping great people build great companies. Since its inception in 1988, the firm has taken a sector-focused approach to investing in exceptional communications, consumer, digital media, healthcare and information technology companies. With over $3 billion of committed capital and offices in Boston, Silicon Valley, Shanghai and Geneva, Highland has invested in and worked to create such firms as Ask Jeeves, Avid Technology, CheckFree, Conor Medsystems, Continental Cable, Helicos BioSciences, lululemon athletica, Lycos, MapQuest, Navic Networks, Ocular Networks, Odyssey Healthcare, P.A. Semi, Quigo, Starent Networks, Sybase, Telica and VistaPrint. For more information, visit Highland's web site at http://www.hcp.com.


'/>"/>
SOURCE Highland Capital Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Stock Exchange Lists Units of Highlands Acquisition Corp.
2. Highlands Acquisition Corp. Completes Initial Public Offering
3. Highlands Acquisition Corp. Announces Exercise of Over-Allotment Option
4. Highlands Acquisition Corp. Announces Separate Trading of Common Stock and Warrants
5. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
6. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
7. The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that building ... the frequency and level of relapse. , At the 2016 iaedp ... will explore the critical tasks of the recovery phase and beyond including relapse ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... COLUMBUS, Ohio, Feb. 4, 2016 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year.  Reported sales ... in the quarter. , Net earnings per diluted ... in the prior- year period.  Adjusted EPS was $4.65, ...
Breaking Medicine Technology: